儿童特应性皮炎影响量表简版CADIS-SF15的验证开发
本研究基于45条目的CADIS量表开发简版。300名患儿家长完成原型量表,经探索性因子分析、内容效度评定和验证性因子分析,最终形成含15条目、3个域的CADIS-SF15。该简版内部一致性、重测信度、结构效度和反应性良好,能区分不同严重度并检测改善。
要点
- CADIS-SF15含15条目、3个域,用于评估AD患儿及家长生活质量。
- 简版内部一致性、48小时重测信度、结构效度和反应性均良好。
- 能区分轻、中、重度AD,并可检测患者随时间改善的变化。
核心结论
- CADIS-SF15是内部一致、可靠、有效、有反应性且简短的AD患儿及家长生活质量评估工具。
- 仍需进一步评估其临床适用性。
研究设计与样本
- 基于45条目CADIS量表开发简版,300名患儿家长完成原型量表。
- 采用探索性因子分析、验证性因子分析和内容效度评定筛选条目。
- 评估简版的内部一致性、48小时重测信度、结构效度和反应性。
主要发现
- 基线270个家庭提供数据,48小时后34个,4周后228个。
- 验证性因子分析显示模型拟合良好,最终形成15条目、3个域的CADIS-SF15。
- 总量表及3个域的内部一致性和重测信度良好。
- SCORAD与其他主观测量的相关性与假设一致,轻、中、重度AD患者得分差异显著。
临床怎么用
- 可用于临床评估AD患儿及其家长的生活质量负担,简版减少填写负担。
- 可辅助区分AD严重程度并追踪病情改善。
局限性
- 临床适用性仍需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Childhood Atopic Dermatitis Impact Scale (CADIS) with 45 items may be burdensome to complete. We therefore aimed to develop a CADIS short-form. METHODS: Parents of 300 children completed the prototype CADIS. Exploratory factor analysis was conducted on the 45-item CADIS version. The most representative items were chosen. Confirmatory factor analysis was used to confirm the a priori factor structure. Content validity was assessed in a focus group of patients, parents, clinicians, methodologists and industry delegates. Internal consistency, 48-h test-retest reliability, construct validity and responsiveness of the newly developed short-form were assessed. RESULTS: A total of 270 families provided data at baseline, 34 after 48 h and 228 after 4 weeks. Fourteen items of three different factors fulfilled the proposed eligibility criteria and were included in the draft short-form. After the content validity rating, one item relating to the child's sleep was added to further improve content validity. The confirmatory factor analyses showed good model fit, and a 15-item short-form was initiated, the CADIS-SF15. The total scale and the three domains showed good internal consistency and test-retest reliability. The correlation between SCORAD and other subjective measures was consistent with our hypotheses. Differences in scores between mild, moderate and severe AD patients were significant, and the CADIS-SF15 was able to detect changes in 'improving' patients over time. CONCLUSION: The CADIS-SF15 with 15 items in three domains is an internally consistent, reliable, valid, responsive and brief measure of QoL in children affected with AD and their parents. Further evaluation of clinical applicability is required.
引用
- Gabes M, Chamlin SL, Lai JS, et al. Development of a validated short-form of the Childhood Atopic Dermatitis Impact Scale, the CADIS-SF15. J Eur Acad Dermatol Venereol. 2020. PMID: 32176387. doi:10.1111/jdv.16362
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。